RAPT Therapeutics to be Acquired by GlaxoSmithKline for $58.00 Per Share in Tender Offer
RAPT has more than doubled off its 52-week low of $5.665.
Summary
RAPT Therapeutics has entered into a definitive agreement to be acquired by GlaxoSmithKline for $58.00 per share in an all-cash tender offer, followed by a merger.
Key Events · M&A and Partnerships · RAPT
-
Definitive Merger Agreement
RAPT Therapeutics has entered into an Agreement and Plan of Merger with GlaxoSmithKline LLC (Parent) and GSK plc (Ultimate Parent).
-
Acquisition Price
GSK will acquire all outstanding shares of RAPT Therapeutics common stock for $58.00 per share in cash.
-
Transaction Structure
The acquisition will be effected through a tender offer, followed by a second-step merger under Section 251(h) of Delaware law.
-
Offer Commencement
The tender offer is expected to commence no later than February 2, 2026.
Analysis · RAPT · Life Sciences
This filing announces a definitive agreement for GlaxoSmithKline (GSK) to acquire RAPT Therapeutics. The offer price of $58.00 per share represents a significant premium to the company's 52-week high and provides immediate liquidity and a clear exit for shareholders. This is a thesis-altering event, as RAPT Therapeutics will cease to be an independent public entity, integrating its pipeline and operations into GSK. Investors should tender their shares once the offer commences.
At the time of this filing, RAPT was trading at $57.45 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $972.7M. The 52-week trading range was $5.67 to $42.39. This filing was assessed with positive market sentiment and an importance score of 10 out of 10.